Dual-Affinity Nanoparticles for Leukocyte-Mediated CTC Targeting
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current nanoparticle systems face challenges in targeting circulating tumor cells (CTCs) due to brevity of circulation time, renal and hepatic clearance, and immune responses, leading to ineffective treatment of cancer metastasis.
Innovation Solution
Dual affinity nanoparticles with different binding affinities for non-cancer and cancer cells, using a weak, reversible bond with healthy leukocytes for circulation and a strong, irreversible bond with CTCs, allowing targeted delivery of therapeutic agents.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Duration of action of moving object
If nanoparticles are designed to circulate in the bloodstream to reach circulating tumor cells, then they can potentially target CTCs, but they are rapidly cleared by renal and hepatic mechanisms and immune responses, resulting in brief circulation time
Solution Approach 1:
The patent uses healthy leukocytes as intermediary carriers to transport nanoparticles to circulating tumor cells. The nanoparticles bind to leukocytes via E-selectin ligands, allowing them to hitchhike through the bloodstream protected from clearance mechanisms. This intermediary approach enables prolonged circulation time while avoiding direct interaction with renal and hepatic clearance systems.
Solution Approach 2:
The patent exploits the natural physiological function of leukocytes to migrate through blood vessels and tissues. By engineering nanoparticles to bind to leukocyte surface markers (E-selectin ligands), the system leverages the body's own cell trafficking mechanisms for delivery, allowing nanoparticles to circulate as long as leukocytes remain in circulation without requiring active propulsion or external control.
2Reliability
If nanoparticles bind strongly to target cells to ensure effective delivery, then therapeutic efficacy improves, but they may also bind to non-cancerous cells, causing off-target effects and reducing specificity
Solution Approach 1:
The patent applies different binding affinities to different targets: strong binding (high affinity) to circulating tumor cells expressing specific markers, and weak binding (low affinity) to healthy leukocytes. This differential affinity design ensures that nanoparticles remain attached to leukocytes during circulation but transfer efficiently to CTCs upon encounter, maximizing therapeutic efficacy while minimizing off-target effects on healthy tissues.
Solution Approach 2:
The patent creates a dynamic binding system where nanoparticle-leukocyte interactions are reversible and transient, allowing nanoparticles to remain in circulation. Upon encountering CTCs, the binding becomes stable and persistent, ensuring effective therapeutic delivery. This dynamic transition from weak/reversible to strong/irreversible binding resolves the contradiction between circulation time and therapeutic efficacy.
3Reliability
If nanoparticles are designed to target circulating tumor cells that are freely floating in the bloodstream, then they can prevent metastasis, but they encounter platelets, plasma proteins, and blood cells that trigger immune responses and particle breakdown
Solution Approach 1:
The patent uses leukocytes as protective intermediaries that shield nanoparticles from immune surveillance and degradation in the bloodstream. By binding to leukocytes, nanoparticles gain protection from platelets and plasma proteins that would otherwise trigger immune responses or cause particle breakdown. The leukocyte coat acts as a biological camouflage that enables nanoparticles to navigate the hostile circulatory environment.
Solution Approach 2:
The patent converts the natural immune system's tendency to clear foreign particles into a beneficial protective mechanism. By designing nanoparticles to mimic leukocyte surface markers (E-selectin ligands), the system exploits the body's own cell recognition and protection mechanisms. What would normally be a harmful immune response to foreign nanoparticles is transformed into a protective effect where the immune system's clearance mechanisms are bypassed through legitimate biological mimicry.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Enhances nanoparticle circulation time, protects against clearance, and effectively induces apoptosis in CTCs, preventing metastasis.
Implementation Method 1
a first targeting agent that binds to a non-cancer cell surface moiety... the relative affinity of said first targeting agent to said second targeting agent is such that the second targeting agent binding with the cancer cell surface moiety will outcompete the first agent binding with the non-cancer cell surface moiety
Implementation Method 2
a second targeting agent that binds to a cancer cell surface moiety... the relative affinity of said first targeting agent to said second targeting agent is such that the second targeting agent binding with the cancer cell surface moiety will outcompete the first agent binding with the non-cancer cell surface moiety
Implementation Method 3
Effective administration of the delivery particle results in the death of the cancer cell... effectively induces apoptosis in CTCs
Data Source
AI summary
The present disclosure described bi-functional delivery particles with the ability to bind to two different cell types in a distinct fashion. Employing a first ligand with differential binding capabilities, the delivery particles may bind to a first target, such as cell, in a reversible fashion such that when they encounter a second target (e.g., cell) a second ligand that bind irreversibly to the second target will disrupt the binding to the first target. As such, the first target acts as a carrier to delivery the particle to a diagnostic or therapeutic second target. In particular aspects, the first and second cells are circulating cells.